The biopharmaceutical industry is responding to Trump’s call to put America first by announcing three major actions to lower ...

GSK plc names new CEO as shares rise 3% and maintains a 4% dividend yield; get key insights on GSK stock's outlook and what ...

President Trump’s new pharmaceutical tariff policy throws another wrench into an already increasingly complex drug supply chain, with experts calling for more clarity and details into the ...

What unnerves investors is a lack of clarity on drug pricing.

The details of the president’s proposed tariffs were not clear. But it seemed that many big companies would qualify for ...

On Sept. 25, President Donald Trump announced that 100% tariffs on branded or patented pharmaceuticals will be enacted ...

Drugmakers are scrambling to make last-minute announcements ahead of a Trump deadline on Monday for the firms to lower U.S.

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing ...

Just because a supplement is "natural" doesn't mean it won't cause negative side effects. If it has the potential to help, it has the potential to harm. This is especially true if it's used improperly ...

Some of the biggest pharmaceutical firms in the US are nearing the end of multibillion-dollar patent windfalls as their ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.